ANTI-SCARRING 

Tcellexa ECHNOLOGY

ANTI-SCARRING GENE THERAPY

Cellastra is piondering  

I'm a paragraph. Click here to add your own text and edit me. It's easy.

VIREXA FOR MITIGATION OF PANDEMICS SUCH AS COVID-19

VIREXA  is a formulation for inhalation by hugh risk patients in a pandemic such as COVID-19, e.g.. elderly or other patients wiith risk factors for develop ing long-term complications with fibrosis. An  intramuscular injection may potentially prevent multi organ damages.

CELLEXA TO PREVENT DERMAL SCARRING AFTER BURN INJURIES

Gene therapy for dermal aaplication to revent  scarring after burn injury..

Applied topically by spray or ointment suitable for larger body surface area.  

CELLEXA TO PREVENT DERMAL SCARRING AFTER SURGERY

for prevention of dermal scarring after surgery, e.g. breast implant or C-section. Applied as gel before wound closure or injected subcuteneously into the wound area in cosmetically challening areas such as the face, mammoplasty or after C-section..

HOW DOES IT WORK?

• CELLLEXA iand VIREXA are formulations of an effective transport vehicle  (viral vector)

• Programmed with the genetic code for a  lactoferrin derived anti-scarring peptide. 

• Applied under the skin before wound closure after surgery or burn innjuries  (CELLEXA) or inhaled after e. Covid Infection (VIREXA) delivers the code  for am antiscarring peptide to the targeted cells.

• IMay Enable  continuous production  of anti-scarring peptides  in the  cells of the wound area for many weeks or months. May Help mitigate hyper immune response (c"ytokine storm"), excessive fibrin formation, secondary infections and excessive scar/ fibrosis  formation

​

​

THE PEPTIDE DISRUPTS ROOT CAUSES OF SCARRING

​